{
    "pmcid": "9884143",
    "qa_pairs": {
        "How does the yeast display method contribute to the development of nanobodies against SARS-CoV-2 variants?": [
            "It allows for the parallel interrogation of a vast number of nanobodies",
            "It increases the size of nanobodies for better binding",
            "It reduces the cost of nanobody production",
            "It enhances the immunogenicity of nanobodies"
        ],
        "What advantage do nanobodies have over conventional monoclonal antibodies as mentioned in the paper?": [
            "Smaller size allowing better tissue penetration",
            "Higher molecular weight for increased stability",
            "Ability to bind to non-protein viral components",
            "Longer half-life in the bloodstream"
        ],
        "What is one potential application of the nanobody repertoires generated by the yeast display method?": [
            "Developing effective therapeutics against current and future SARS-CoV-2 variants",
            "Creating vaccines for unrelated viral infections",
            "Enhancing the immune response to bacterial infections",
            "Producing monoclonal antibodies for cancer treatment"
        ],
        "What is the primary target for vaccines and antibody-based therapies against SARS-CoV-2 according to the paper?": [
            "The receptor-binding domain (RBD) of the spike protein",
            "The nucleocapsid protein",
            "The membrane protein",
            "The envelope protein"
        ],
        "What technique was used in the study to generate nanobodies with novel specificities and improved binding to variants?": [
            "DNA shuffling of complementarity-determining regions (CDRs)",
            "CRISPR-Cas9 gene editing",
            "Protein crystallization",
            "RNA interference"
        ]
    }
}